MingMed Biotechnology présente des données positives de phase II sur le QA102 oral pour le traitement de la dégénérescence maculaire liée à l'âge (DMLA) intermédiaire lors de la réunion 2026 de l'Association for Research in Vision and Ophthalmology (ARVO)

Phase 2positiveQA102Positive

AI Analysis

Summary

MingMed Biotechnology announced positive Phase II trial results for QA102, an oral treatment for intermediate age-related macular degeneration, presented at the 2026 ARVO conference.

Clinical Trial Data

Phase

Phase II

Primary Endpoint

Met

Outcome Details

positive Phase II clinical trial results for oral QA102

Importance:6/10

Sentiment:

0.75

ophthalmologymacular degenerationPhase 2 dataoral formulation

Related Companies

$VMAR

Read the original article

Published by PR Newswire Biotech on May 6, 2026 12:28 AM

Read Original